Liraglutide Cipla 6 mg/ml Solution for injection in a pre-filled pen
PDF Leaflet Revision Date: 21 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to diet and exercise for glycaemic control in type 2 diabetes.
Dosage (summary)
Start with 0.6 mg daily, increase to 1.2 mg after 1 week, max 1.8 mg.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Sulphonylureas
- Insulin
- Warfarin
Contraindications
- Hypersensitivity to liraglutide
- History of pancreatitis
- Type 1 diabetes
Common side effects
- Nausea
- Diarrhoea
- Vomiting
- Headache
Counselling Points
- Rotate injection sites
- Monitor for gastrointestinal effects
- Avoid dehydration
Serious warnings
- Risk of pancreatitis
- Hypoglycaemia with sulphonylureas
- Injection site reactions
Important Disclaimer
The Liraglutide Cipla 6 mg/ml Solution for injection in a pre-filled pen professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
